T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can’t easily distinguish cancerous T cells from healthy ones. Now, scientists at The Wistar Institute have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity but counters the evasion strategy the cancer employs in response.
This article was originally published on MedicalXpress.com

